Differential Expression between Human Dermal Papilla Cells from Balding and Non-Balding Scalps Reveals New Candidate Genes for Androgenetic Alopecia by Chew, EGY et al.
Accepted Manuscript
Differential expression between human dermal papilla cells from balding and non-
balding scalps reveals new candidate genes for androgenetic alopecia
E.G.Y. Chew, J.H.J. Tan, A.W. Bahta, B.S.-Y. Ho, X. Liu, T.C. Lim, Y.Y. Sia, P.L.
Bigliardi, S. Heilmann, A.C.A. Wan, M.M. Nöthen, M.P. Philpott, A.M. Hillmer
PII: S0022-202X(16)31024-7
DOI: 10.1016/j.jid.2016.03.032
Reference: JID 283
To appear in: The Journal of Investigative Dermatology
Received Date: 16 March 2015
Revised Date: 9 March 2016
Accepted Date: 24 March 2016
Please cite this article as: Chew EGY, Tan JHJ, Bahta AW, Ho BS-Y, Liu X, Lim TC, Sia YY, Bigliardi
PL, Heilmann S, Wan ACA, Nöthen MM, Philpott MP, Hillmer AM, Differential expression between
human dermal papilla cells from balding and non-balding scalps reveals new candidate genes for
androgenetic alopecia, The Journal of Investigative Dermatology (2016), doi: 10.1016/j.jid.2016.03.032.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Manuscript Title: Differential expression between human dermal papilla cells from balding and 
non-balding scalps reveals new candidate genes for androgenetic alopecia 
 
E.G.Y. Chew1, J.H.J. Tan1, A.W. Bahta2, B.S.-Y. Ho3, X. Liu1, T.C. Lim4, Y.Y. Sia1, P.L. 
Bigliardi3,5,6, S. Heilmann7,8, A.C.A. Wan4, M.M. Nöthen7,8, M.P. Philpott2, A.M. Hillmer1 
 
1Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore, Singapore; 
2Centre for Cutaneous Research, Institute of Cell and Molecular Science, Barts and The London, Queen 
Mary's School of Medicine and Dentistry, Queen Mary College, London, UK; 3Experimental 
Dermatology Group, Institute of Medical Biology, Singapore, Singapore; 4Cell and Tissue Engineering, 
Institute of Bioengineering and Nanotechnology, Singapore, Singapore; 5National University of 
Singapore, YLL School of Medicine, Singapore, Singapore; 6Department of Medicine, National 
University Hospital, Singapore, Singapore; 7Institute of Human Genetics, University of Bonn, Bonn, 
Germany; 8Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany 
 
Correspondence: Axel M. Hillmer, Genome Institute of Singapore, 60 Biopolis Street, #02-01 Genome, 
Singapore 138672, Singapore, Tel: +65 6808 8076, Fax: +68 6808 8304, Email: hillmer@gis.a-
star.edu.sg 
 
Study conducted in Singapore, Singapore and London, UK. 
 
Short title: Expression differences in balding and non-balding human DPC 
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Data Deposition: The data reported in this paper have been deposited in Gene Expression Omnibus, 
http://www.ncbi.nlm.nih.gov/geo (GEO Series accession number GSE66663 and GSE66664) 
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ABSTRACT 
Androgenetic alopecia (AGA) is a common heritable and androgen-dependent hair loss condition in men. 
Twelve genetic risk loci are known to date but it is unclear which genes at these loci are relevant for 
AGA. Dermal papilla cells (DPC) located in the hair bulb are the main site of androgen activity in the hair 
follicle. Widely used monolayer-cultured primary DPC in hair-related studies often lack dermal papilla 
(DP) characteristics. In contrast, immortalised DPC have high resemblance to intact DP. We derived 
immortalised human DPC lines from balding (BAB) and non-balding (BAN) scalp. Both BAB and BAN 
retain high proportions of DP signature gene and versican protein expression. We performed expression 
analysis of BAB and BAN and annotated AGA risk loci with differentially-expressed genes. We found 
evidence for AR but not EDA2R as the candidate gene at the AGA risk locus on chromosome X. Further, 
our data suggest TWIST1 and SSPN to be the functionally relevant AGA genes at the 7p21.1 and 12p12.1 
risk loci, respectively. Down-regulated genes in BAB compared to BAN were highly enriched for 
vasculature-related genes, suggesting that deficiency of DPC from balding scalps in fostering 
vascularisation around the hair follicle may contribute to the development of AGA. 
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INTRODUCTION 
Androgenetic alopecia (AGA) is a prevalent hair loss condition that affects up to 80% of European males 
by age eighty (Hamilton, 1951) and is characterised by bitemporal regression of hair growth in 
combination with hair loss at the vertex (Trueb, 2002). AGA development is attributed to androgen 
dependence (Hamilton, 1942) and genetic predisposition (Nyholt et al., 2003; Rexbye et al., 2005). The 
X-chromosomal androgen receptor (AR)/ectodysplasin A2 receptor (EDA2R) locus was the first described 
and replicated risk locus for AGA (Ellis et al., 1998; Prodi et al., 2008). In recent years, a total of 12 
AGA risk loci have been described (Brockschmidt et al., 2011; Heilmann et al., 2013; Hillmer et al., 
2008; Li et al., 2012; Richards et al., 2008). However, the genes causative for increased AGA risk at the 
majority of the risk loci are still unclear. Functional understanding of AGA biology is lacking as it is not 
trivial and scalable to dissect the different compartments of hair follicles. Appropriate model systems for 
AGA are also unavailable. Medical treatments for AGA include minoxidil, which is hypothesized to 
promote hair growth by increasing vascular endothelial growth factor (VEGF) expression in dermal 
papilla cells (DPCs) during the growth (anagen) phase of the hair cycle. DPCs, located at the base of the 
hair follicle, are essential in the hair growth process. DPCs have the most consistent AR expression among 
all compartments of the hair follicle (Hodgins et al., 1991) and thus are the postulated sites of androgen 
response, where AR activation by androgens affect gene expression regulating hair growth and cycle 
(Itami et al., 1994; Kitagawa et al., 2009). To date, only a macroarray-based comparative study 
interrogating 1,185 genes has been conducted on primary DPCs from balding and non-balding scalps 
(Midorikawa et al., 2004). The limited life span of primary cell lines hampers complex and long term 
experiments. 
In this study we present a robust and practical model system for AGA. We immortalised two human DPC 
lines, one derived from a balding vertex scalp area (BAB) and one derived from a non-balding occipital 
scalp area (BAN) and determined that both cell lines possess DP character. The utility of single cell lines 
are supported by their usage in discovery (Edwards et al., 1980; Elenbaas et al., 2001) and functional 
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studies (Boukamp et al., 1988) for various disease conditions. We analysed BAB and BAN gene 
expression alterations in response to DHT treatment by microarray technology interrogating 26,000 genes 
and used the expression information to interpret described AGA risk loci. Further, we identified 
differentially-expressed genes between balding and non-balding DPCs revealing down-regulation of 
vasculature-related genes in DPCs of balding hair follicles.  
 
RESULTS 
Immortalised balding and non-balding DPC retain DP character 
Immortalised balding DPC (BAB; Figure 1a) and non-balding DPC (BAN; Figure 1b) established from 
biopsies of balding and non-balding scalps of male patients by hTERT (human telomerase reverse 
transcriptase) expression were observed to have different cell morphologies. Both BAB and BAN retained 
DP characteristics after in vitro two-dimensional (2D) culturing, as indicated by the high expression of 
VCAN (versican) protein (Figure 1c and d), and the expression of human DP signature genes (Ohyama 
et al., 2012), with 83 out of 117 (70.9%, p < 0.001) and 75 out of 117 (64.1%, p < 0.05) of DP signature 
genes expressed in BAN and BAB, respectively (Figure 1e and S2, Table S1a). DP signature genes have 
previously been defined as significantly up-regulated genes in freshly-dissected DP compared to dermal 
fibroblasts (Ohyama et al., 2012). We observed similar fractions of DP signature gene expression in 
primary non-balding DP (n = 2) and primary balding DP (n = 3) cells which expressed 79 out of 116 
(68.1%, p < 0.01) and 69 out of 116 (59.5%, p < 0.05) DP signature genes, respectively (Table S1b). 
Furthermore, we found that DP signature gene expression profile of both BAN and BAB were more 
similar to primary occipital DPC (HFDPC) than to primary fibroblasts (L5-F and NHDF) 
(Supplementary Results, Figure S3, Table S1a and S1c).  
Differential gene expression analysis between BAB and BAN 
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Both inherent and DHT-dependent gene expression differences were found to be present between BAB 
and BAN (Figure 2a). Among the differentially expressed genes in BAB compared to BAN under 1 nM 
and 10 nM of DHT stimulation, 1,482 and 1,508 genes were found to be commonly up-regulated and 
down-regulated, respectively (Figure 2c and d; Table S2a and S2b). Subsequent analysis was carried out 
with commonly up- and down-regulated genes between both DHT concentrations. The trend of 
expression of qPCR validated genes (CAV1 (caveolin 1), EDNRA (endothelin receptor type A), IGFBP5 
(insulin-like growth factor binding protein 5), and SCG2 (secretogranin II)) was consistent with that from 
the microarray data (Figure 2e-h).  
Annotation of AGA risk loci with differentially-expressed genes in BAB compared to BAN 
Genome-wide association studies (GWAS) have identified genomic loci which confer risk to develop 
AGA. However, it is largely unclear which genes at these loci are causal for the associations. Our tissue 
and phenotype-specific expression data allowed us to infer which genes at the risk loci most likely 
contribute to AGA development. Twelve differentially-expressed genes in BAB compared to BAN 
overlapped within 500 kb of seven lead SNPs at established AGA risk loci (Table 1 and S8). On Xq12, 
the major AGA risk locus, AR was up-regulated in BAB compared to BAN suggesting that AR rather than 
the centromeric EDA2R contributes to AGA. At the 2q37 risk locus, only PER2 and TWIST2 showed 
expression differences within 500 kb from the lead SNP rs9287638, and therefore are more likely 
candidate genes at this locus than non-differentially expressed HDAC4. At the 5q33.3 risk locus, down-
regulated RNF145 is a potential candidate gene. Up-regulation of TWIST1 was found at the 7p21.1 risk 
locus. Furthermore, our finding of 7q11.22 candidate gene AUTS2 being down-regulated in BAB 
compared to BAN is in agreement with a previous study (Li et al., 2012) which suggested AUTS2 as the 
candidate gene causing the association of this locus with AGA. On 12p12.1, SSPN showed down-
regulation and is the more likely candidate gene at this locus instead of non-differentially expressed 
ITPR2. On 17q21.31, down-regulated gene MAPT is the likely candidate gene instead of non-
differentially expressed SPPL2C.  
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Gene ontology analysis of differentially-expressed genes in BAB as compared to BAN 
Down-regulated genes in BAB compared to BAN under DHT treatment were found to be most enriched 
in gene ontology (GO) clusters related to vasculature (max enrichment score = 10.516; 65 genes) and 
included the sub-terms of vasculature development, blood vessel development and blood vessel 
morphogenesis (Figure 3a; Table 2, S3a and S4a). We found support for vasculature-related differences 
between BAB and BAN by immunofluorescence (Figure 3c and d) and migration assay experiments 
(Figure S5 and Supplementary Results). We tested the down-regulated vasculature-related genes 
CAV1, CYR61 (cysteine-rich, angiogenic inducer, 61) and MMP14 (matrix metallopeptidase 14) by 
immunofluorescence and observed protein down regulation for MMP14 (p = 0.0004) and CAV1 (p = 
0.0002) in BAB compared to BAN (Figure 3c and d). A significant number of the identified vasculature-
related genes (Table 2 and S3a) were also found to be down-regulated in independent samples of primary 
balding (n = 3) compared to non-balding DPC (n = 2; p < 0.001; 16 out of 65: Table S3c, 
Supplementary Results). Up-regulated genes were most enriched in GO clusters related to cell cycle and 
mitosis (max enrichment score = 38.551; 139 genes; Figure 3b and Table S4b).  
Motif analysis in promoters of differentially-expressed genes in BAB compared to BAN 
We performed a transcription factor (TF) motif enrichment analysis in promoters of differentially-
regulated genes in BAB compared to BAN to investigate potential TF implicated in characteristic 
differences between the cell types. The SIX1 motif which was enriched in promoters of down-regulated 
genes (Table S2b and S9a) is implicated in hair placode development (Rhee et al., 2006). While enriched 
motifs in the promoters of up-regulated genes (Table S2a and Table S9b) include E2F and CHR motifs 
which correlate with biological function in cell cycle and mitosis (Figure 3b; Table S4b). We have also 
identified genes which could be synergistically regulated by multiple TF due to the co-occurrence of E2F, 
NFY and CHR sites (Table S9d) (Tabach et al., 2005) (Supplementary Results). 
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DISCUSSION 
In this study, we have demonstrated that both 2D-cultured immortalised balding DPC and non-balding 
DPC maintained DP characteristics and therefore provide a model for studying AGA and hair biology. 
First, both BAB and BAN retained significant expression of a majority of DP signature genes (BAB: 
64.1%, p < 0.05; BAN: 70.9%, p < 0.001; Figure 1e and Table S1a) defined from expression profiling of 
freshly-dissected human DPs (Ohyama et al., 2012). DP signature genes interrogated for include classical 
DP signature genes such as ALPL, WIF1, LEF1 (Kratochwil et al., 1996) and VCAN (Ohyama et al., 
2012; Soma et al., 2005), of which ALPL, LEF1, and VCAN were expressed in BAB and BAN (Figure 1e 
and Table S1a). Second, both DPC lines stained positively for VCAN protein which expression is 
correlated with DP inductivity and hair morphogenesis (Kishimoto et al., 1999; Soma et al., 2005). The 
BAB and BAN cell lines serve as a useful model system for AGA as they are simple to maintain in 
culture, requiring only FBS-supplemented media. In contrast, primary DPC which are widely used in 
hair-related studies are less ideal models, as primary DPC lose DP character upon 2D-culturing (Higgins 
et al., 2013) and are challenging to maintain in culture over extended periods. We were only able to 
immortalise balding and non-balding DPC from non-matched patient biopsies as primary balding DPC 
were prone to senescence during the initial culturing process and had low success rates for 
immortalisation. The difficulty of establishing immortalised DPC lines are further evidenced by the lack 
of such cell lines to date, to the best of our knowledge. Further, we would like to emphasize that single 
cell lines such as HaCaT (Boukamp et al., 1988), MCF7 (Edwards et al., 1980) and HMEC (Elenbaas et 
al., 2001) have contributed significantly to our understanding of cell type-specific behaviour and serve as 
disease models. It is desirable to establish more balding and non-balding DP cell lines to validate the 
transcriptomic signatures. Further, cell lines from vertex with full hair should be included to dissect 
balding-specific from vertex-specific signatures. 
We annotated AGA risk loci with differentially-expressed genes in BAB compared to BAN and found 
differential gene expression in seven out of the twelve interrogated genomic regions (Table 1 and S8). 
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Notably, we found AR to be the likely candidate gene at the major risk locus for AGA (Xq12, rs2497938) 
instead of EDA2R. This is consistent with previous observations of higher AR levels in balding scalps 
(Hibberts et al., 1998) and reinforced the importance of the androgen/AR interaction in AGA 
development. Furthermore, the identification of MAPT as the relevant AGA candidate gene at 17q21.31 
instead of SPPL2C suggests that changes in MAPT function connect the risk for AGA with the risk for 
Parkinson’s disease (Li et al., 2012). 
None of the candidate genes at the 20p11 susceptibility locus (rs6047844), FOXA2 (forkhead box A2) and 
PAX1 (paired box 1), were differentially expressed between BAB and BAN. PAX1, but not FOXA2, was 
expressed in BAB and BAN. The lack of differentially-expressed genes within 500 kb from rs6047844 
suggest (i) that this susceptibility region may be involved in long-range chromatin interaction that result 
in the regulation of distant candidate genes, or (ii) that DPCs are not the cell type which confers the AGA-
related functional effect of this locus or (iii) that the BAN/BAB model cell lines do not preserve this 
characteristic. 
At the 1p36 locus, non-differentially-expressed candidate gene TARDBP (TAR DNA binding protein) is 
unlikely to be causative. Instead, SRM, previously mentioned as a potential candidate gene due to its 
proximity to rs12565727 (Li et al., 2012), was up-regulated in BAB compared to BAN. SRM is involved 
in the synthesis of spermidine which acts on matrix keratinocytes to promote hair elongation and prolong 
anagen (Ramot et al., 2011). However, the effect of SRM activity and the resultant spermidine 
synthesized in DPC is unknown. Further, we found CASZ1, EXOSC10, FRAP1, and UBIAD1 to be 
differentially-expressed at this locus. They provide new potential candidate genes for hair loss/growth 
modulation.  
The candidate genes HDAC4, EBF1 and HDAC9 at susceptibility loci 2q25, 5q33.3 and 7p21.1, 
respectively, were not differentially-expressed between BAB and BAN and thus are unlikely to be the 
causative genes at these loci. Instead, we found four other differentially-expressed genes in BAB 
compared to BAN as potential candidates. RNF145, located at 5q33.3, is implicated in endoplasmic 
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reticulum-associated protein degradation (Kikkert et al., 2004) and apoptosis (Ho et al., 2014). At the 
7p21.1 locus, we found TWIST1, a DP signature gene expressed in both BAB and BAN (Figure 1e and 
Table S1) being up-regulated in BAB (Table 1). Twist1, a bHLH (basic helix-loop-helix) protein, is 
crucial for anagen-to-catagen transition during the hair growth cycle as Twist1 protein ablation in adult 
mice DP result in prolonged anagen (Xu et al., 2013). Hence, TWIST1 up-regulation in DPC of balding 
scalps as compared to non-balding scalps may result in accelerated transition from anagen to catagen and 
thus shortened period of anagen during the hair cycle; a phenomenon in balding scalps that leads to the 
formation of short vellus hairs instead of long terminal hairs (Paus and Cotsarelis, 1999). Furthermore, 
bHLH proteins such as Twist1 bind to the consensus 5’-NCANNTGN-3’ E-box motif, thus the down-
regulation of genes in BAB compared to BAN with E-box motif in their promoter regions (Table S9a; 
Supplementary Results) may be attributed to repression by TWIST1. Interestingly, we identified another 
TWIST protein, TWIST2, as a potential candidate gene at the 2q37 risk locus. TWIST2 has been 
implicated in mesenchymal cell lineage development (Li et al., 1995) but little is known about its function 
in the DP. The combinatorial binding and interaction of TWIST1 and/or TWIST2 with other bHLH 
proteins (Franco et al., 2010) at the promoters of target genes may result in gene regulation in DPC. 
TWIST1 also interacts and binds to HDAC4 (Danciu and Whitman, 2009) to regulate gene expression 
(Gong and Li, 2002; Lee et al., 2003). In addition, binding of TWIST1 at E-boxes in the AR promoter 
region result in up-regulated AR expression (Shiota et al., 2010). Our observation of both TWIST1 and AR 
up-regulation in BAB as compared to BAN could be attributed to increased regulation of AR expression 
by the increased TWIST1 levels in BAB compared to BAN. This potential relationship between AR and 
TWIST1 in balding DPC, which to our knowledge has not been considered previously, provides support 
for these two candidate genes to be the causative AGA genes at the 7p21.1 and Xq12 susceptibility loci.  
Down-regulated genes in BAB compared to BAN were significantly enriched in vasculature-related GO 
cluster (Figure 3a; Table 2 and S3a), with 41.5% (27 genes) of the vasculature-related genes (Table S3a) 
being down-regulated in BAB compared to BAN through DHT treatment (Table S3b). Moreover, a 
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significant number of vasculature-related genes identified (Table 2 and S3a) were also found to be down-
regulated in independent samples of primary balding DPC as compared to non-balding DPC (p < 0.001; 
16 out of 65: Table S3c, Supplementary Results). The Maz motif, which has been found in promoters of 
angiogenesis-related genes (Yang et al., 2008), was enriched in down-regulated genes in BAB compared 
to BAN (Table S9a). Furthermore, a trend analysis suggested less coherent vasculature-related gene 
expression changes in BAB compared to BAN over time (Figure S8). Hair follicle vascularisation affects 
follicle size and length (Yano et al., 2001), with arrangement and density of vasculature altering during 
anagen (Durward and Rudall, 1958) and catagen (Ellis and Moretti, 1959). Reduced vasculature has also 
been observed around DP of balding vertex scalps as compared to non-balding scalps (Cormia and 
Ernyey, 1961). The ability to attract endothelial cells for follicular vasculature network regeneration is 
therefore closely tied to hair follicle cycling and growth.  
In summary, the immortalised DPC lines, BAB and BAN, introduced in this study provide a useful 
resource for AGA-related studies. We identified a set of vasculature-related genes which were down-
regulated in balding DPC under the influence of DHT. With the limitation that our finding is based on 
two individual cell lines only, we suggest that DPC in balding scalps may be deficient in fostering 
vasculature development as compared to DPC in non-balding scalps. Further in-depth studies are required 
for validating this finding, deciphering the contribution of identified molecular elements in altering 
vasculature in the hair follicle and whether this underlies the development of AGA. Our annotation of 
AGA risk loci with (differentially) expressed genes in BAB compared to BAN has shown that it is 
insufficient to rely solely on expression of proximal genes to lead association SNPs for candidate gene 
discovery at susceptibility loci. Our findings point to AR as the candidate gene at the lead AGA risk locus 
on chromosome X. We also identified TWIST1 as a functionally relevant gene for AGA at the 7p21.1 
susceptibility locus. In depth studies are required to ascertain the causative role of these candidate genes 
in the development of AGA. 
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MATERIALS AND METHODS 
Isolation and immortalisation of human balding and non-balding primary DPC 
Between one and three DP were isolated from each matched 2 mm punch biopsies of balding (frontal) and 
non-balding (occipital) scalps of male AGA patients who were undergoing hair transplant surgery and not 
currently on hair loss medications, as described previously (Bahta et al., 2008; Philpott et al., 1994; 
Upton et al., 2015). Ethics approval was obtained from East London and City health authority (T/98/008) 
and all biopsies were taken with full patient written consent. All experiments adhered to the Declaration 
of Helsinki Principles. Isolated primary DPCs were cultured up to passage 3 (Supplementary Materials 
and Methods) and immortalised with hTERT using pBABEhygro-hTERT. Hygromycin-resistant clones 
with stable hTERT expression were then cultured as described in the Supplementary Materials and 
Methods. We were able to derive one immortalized balding (BAB) and one non-balding (BAN) cell line 
originating from two different male individuals due to limitation in tissue materials, difficulties in 
establishing pure primary DPC cultures and low transformation efficiencies. Both BAB and BAN have 
been established from Anglo-Saxon males with Hamilton scale 4 AGA. 
Microarray and processing 
Gene expression in BAB, BAN, primary occipital DPC (HFDPC) and primary fibroblasts (L5-F and 
NHDF) were interrogated with HumanHT-12 v4 BeadChip arrays (Illumina, St. Diego, CA). Gene 
expression of 3 primary balding DPC (Passage 2) and 2 primary non-balding DPC (Passage 2) were 
interrogated with HG 133A GeneChips arrays (Affymetrix Inc., Santa Clara, CA) (Figure S1, 
Supplementary Materials and Methods). All 5 primary DPC samples and the immortalised BAB and 
BAN were isolated from independent subjects. 
Characterisation of BAB and BAN 
Immunostaining for versican was conducted on BAB and BAN to determine expression of DP marker 
(Supplementary Materials and Methods). Expression of 117 DP signature genes was interrogated in 
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BAB, BAN, primary balding and non-balding DPC from AGA individuals, primary occipital DPC 
(HFDPC) and primary fibroblasts (L5-F and NHDF) (Supplementary Materials and Methods). Gene 
expression of DP signature genes was also validation by RT-qPCR in BAB and BAN (Supplementary 
Materials and Methods). 
Differential gene expression analysis between BAB and BAN  
BAB and BAN were conditioned in phenol red-free DMEM media for 24 hr, and treated with 1 nM or 10 
nM DHT for 15 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr, 18 hr, 20 hr, 24 hr, 36 hr and 48 hr prior to microarray 
analysis. GO analysis was then carried out on differentially expressed genes found in BAB as compared 
to BAN under both 1 and 10 nM DHT treatment (Figure S1, Supplementary Materials and Methods). 
The concentration of DHT applied on DPC was within the adult human male physiological DHT serum 
levels (Cailleux-Bounacer et al., 2009; Feldman et al., 2002). Expression of differentially-expressed 
genes CAV1, EDNRA, IGFBP5 and SCG2 were also validation by RT-qPCR (Supplementary Materials 
and Methods). Immunostaining for CYR61, MMP14 and CAV1 was conducted to validate expression of 
differentially-expressed genes (Supplementary Materials and Methods). 
Annotation of AGA risk loci with differentially-expressed genes in BAB as compared to BAN 
As differentially-expressed genes at the risk loci were likely to be causative genes that contribute to AGA 
development, we overlapped differentially expressed genes with 12 lead SNPs with genome-wide 
association significance using upstream and downstream windows of 500 kb, 100 kb and 50 kb 
(Supplementary Materials and Methods). 
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Table 1: Overlap of differentially-expressed genes identified in balding DPC (BAB) compared to non-balding DPC (BAN) with AGA risk loci of 
genome-wide significance 
     
500kb 
 
100kb 
 
50kb 
 
Median fold 
change 
Chr  Position1 SNP2 Genomic 
region Genes
3 Diff genes4 Up/ down5   Diff genes
4
 
Up/ 
down5   
Diff 
genes4 
Up/ 
down5   
1nM 
DHT 
10nM 
DHT 
1 11,033,082 rs125657276 1p36  []--TARDBP  
CASZ115 down   - -   - -   2.010 1.945 
EXOSC1015 up   EXOSC1015 up   - -   1.918 1.998 
FRAP115 up   - -   - -   1.740 - 
SRM up   SRM up   - -   2.254 2.122 
UBIAD115 up - - - -   2.154 1.945 
2 219,756,383 rs73493327 2q35 [WNT10A] - -   - -   - -   - - 
2 239,694,631 rs92876386 2q37  []--HDAC4  
PER215 down   - -   - -   1.933 1.909 
TWIST215 down   TWIST215 down   - -   1.949 2.305 
3 151,653,368 rs46799557 3q25.1 SUCNR1--[]---MBNL1 - -   - -   - -   - - 
5 158,310,631 rs9296267 5q33.3 [EBF1] RNF14515 down    - -   - -   1.730 - 
7 18,877,874 rs20739636,8 7p21.1  [HDAC9]  TWIST115 up   - -   - -   2.548 2.244 
7 68,611,960 rs69455416 7q11.22  []---AUTS2  AUTS2 down   - -   - -   2.801 2.868 
12 26,426,420 rs96688107 12p12.1 SSPN--[]--ITPR2 SSPN down   SSPN down   SSPN down   2.197 2.133 
17 43,924,219 rs123731246 17q21.31  [SPPL2C]--MAPT  MAPT down   MAPT down   MAPT down   1.930 1.835 
18 42,800,148 rs105028616 18q21.1  SETBP1---[]  - -   - -   - -   - - 
20 22,037,575 rs6047844
6,9
,10
 
20p11  PAX1--[]--FOXA2  - -   - -   - -   - - 
X  66,563,018 rs2497938
6,1
1,12,13,14
 
Xq12  EDA2R---[]--AR AR up   - -   - -   1.751 1.737 
1
 - Chromosomal position in GRCh37/hg19 assembly; 2 - references include first descriptions of associations of the respective locus that not necessarily have the same SNP; 3 - 
Candidate genes harbouring SNP or in close proximity to SNP; 4 - Differentially-expressed genes in balding DPC (BAB) compared to non-balding DPC (BAN) that are within 
window stated to SNP - up: differentially-expressed gene is up-regulated in BAB compared to BAN, down: differentially-expressed gene is down-regulated in BAB compared to 
BAN; 6 - (Li et al., 2012); 7 - (Heilmann et al., 2013); 8 - (Brockschmidt et al., 2011); 9 - (Hillmer et al., 2008); 10 - (Richards et al., 2008); 11 - (Ellis et al., 2001); 12 - (Hillmer et 
al., 2005); 13 - (Brockschmidt et al., 2010); 14 - (Prodi et al., 2008); 15 - Novel candidate genes not considered by previous publications  
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Table 2: List of vasculature-related genes that are down-regulated in balding DPC (BAB) compared to 
non-balding DPC (BAN) 
Gene Name Median fold change 
 
Gene Name Median fold change 
 
1nM DHT 10nM DHT 
  
1nM DHT 10nM DHT 
ACTC1 2.628 2.532 GNA13 - 1.885 
ADORA2A 1.924 1.752 GUCY1A3 1.832 1.846 
ADRA1B 1.833 1.749 HEY1 2.046 2.402 
ADRB2 2.106 2.590 HIF1A 2.557 2.670 
AGT 2.008 1.881 HIF1A 2.806 2.850 
AGTR1 2.788 2.643 HIF1A 2.822 2.546 
AGTR1 2.803 2.621 HMOX1 1.895 1.934 
AMOT 1.851 1.910 HTATIP2 6.764 6.038 
ANGPTL4 2.054 2.220 ITGA1 2.008 1.956 
ANXA2 2.500 2.211 ITGA4 1.784 1.748 
APOLD1 2.371 2.661 JUNB 2.325 2.002 
BGN 2.314 2.324 KLF5 1.738 1.802 
CAV1 2.884 2.708 LEPR 2.042 1.987 
CAV2 1.857 1.954 LOX 3.116 2.974 
CAV2 1.819 1.775 MMP14 2.090 2.003 
CAV2 1.827 1.741 NOS3 2.154 1.955 
CCBE1 2.250 2.171 NOTCH1 1.713 1.813 
CDH13 1.829 1.867 P2RX4 1.830 1.806 
CDH2 1.734 1.782 PDE5A 2.809 2.697 
CHD7 2.047 2.187 PDPN 1.931 1.957 
CITED2 2.967 2.623 PLAU 1.788 1.882 
COL1A1 5.069 4.926 PLCD3 1.750 1.770 
COL1A2 1.808 1.757 PLXDC1 1.992 1.846 
COL3A1 3.723 3.615 PPAP2B 1.879 1.870 
COL18A1 16.750 15.675 PPAP2B 2.235 2.225 
CTGF 3.546 3.587 RECK 2.463 2.351 
CTGF 3.963 4.229 RECK 2.458 2.314 
CXCL12 2.635 2.631 SCG2 5.365 5.938 
CXCL12 2.391 2.151 SGPL1 1.910 1.828 
CXCL12 2.518 2.643 SMAD7 1.841 1.729 
CYR61 3.167 3.023 SMO 1.783 1.830 
DHCR7 23.464 20.353 SOD2 - 1.752 
DHCR7 17.994 14.520 SOD2 2.306 2.355 
DICER1 1.860 1.800 SOD2 1.969 2.367 
DICER1 1.896 1.898 TGFA 3.281 3.060 
EDNRA 1.831 1.978 TGFA 2.146 2.328 
EREG 1.986 2.303 THY1 2.871 2.781 
FGF2 2.087 2.018 TNFAIP2 3.180 2.792 
FGF2 1.971 1.954 ZC3H12A 1.890 2.237 
GCH1 2.957 3.348 ZFP36L1 3.244 3.055 
GNA13 1.784 1.755 
  
ZMIZ1 1.835 1.746 
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FIGURE LEGENDS 
Figure 1: Characterisation of immortalised balding DPC line (BAB) and non-balding DPC line (BAN). 
(a) BAB grows in a non-monolayer manner and does not cover entire culture area at 100% confluency, 
(b) BAN grows in a monolayer and displays whorl-like pattern. Bar = 1000 µm. Both (c) BAB and (d) 
BAN express dermal papilla marker protein, versican. Cell nuclei marked by DAPI staining (blue). Bar = 
100 µm. (e) 83 out of 117 (70.9%, p < 0.001) DP signature genes were expressed in BAN (green square). 
75 out of 117 (64.1%, p < 0.001) DP signature genes were expressed in BAB (blue square). 69 DP 
signature genes were expressed in both BAN and BAB. 28 DP signature genes not expressed in BAB and 
BAN are listed outside of blue and green squares. 
Figure 2: Differential gene expression in non-balding (BAN) compared to balding DPC (BAB). (a) Gene 
expression in BAN and BAB are inherent and DHT-dependent. (b) Differential genes in BAB compared 
to BAN under 1 and 10 nM DHT treatment, and (c) commonly up- and (d) down-regulated genes under 
both concentrations of DHT stimulation. RT-qPCR validation of down-regulated genes (e) CAV1, (f) 
EDNRA, (g) IGFBP5 and (h) SCG2 in BAB as compared to BAN under 10 nM DHT treatment. 
Expression fold decrease in BAB compared to BAN from microarray analysis presented in upper plots. 
GAPDH-normalised relative gene expression in BAB compared to BAN from RT-qPCR analysis (ddCp) 
presented in the lower plots. Fold change threshold cut-off of 1.7 indicated in red. # indicate fold change 
≤ 1.7 from microarray analysis. 
Figure 3: Gene ontology (GO) clustering analysis of differentially-expressed genes in balding (BAB) 
compared to non-balding DPC (BAN). (a) Down-regulated genes in BAB compared to BAN were highly 
enriched in vasculature-related GO clusters (sub-terms: vasculature development, blood vessel 
development and blood vessel morphogenesis, Table 2), cell motion and cell migration, cell death, 
phosphate and phosphorous metabolism and protein kinase (Table S4a). (b) GO clustering of up-
regulated genes in BAB compared to BAN (Table S4b). Maximum enrichment score of each GO cluster 
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is indicted below respective term. (c,d) Expression levels of vasculature-related proteins, CYR61, 
MMP14 (p = 0.0004) and CAV1 (p = 0.0002) were found to be decreased in BAB compared to BAN. ** 
indicate p < 0.001. Cell nuclei marked by DAPI staining (blue). Bar = 100 µm. HepG2 as negative control 
for CAV1. 
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SUPPLEMENTAL DATA 
Supplementary Materials and Methods 
Supplementary Results 
Supplementary Discussion 
Figure S1: Microarray data analysis pipeline for (a) balding DPC (BAB) and non-balding DPC (BAN) 
samples and (b) primary balding DPC and non-balding DPC 
Figure S2: Validation of eight DP signature genes by RT-qPCR. 
Figure S3: DP signature gene expression in DPC and fibroblast. 
Figure S4: Vasculature-related gene expression in BAB, BAN and fibroblast. 
Figure S5: Validation of vasculature-related differences in balding DPC (BAB) compared to non-balding 
DPC (BAN) with transwell endothelial cell migration assay. 
Figure S6: Overlap of differential genes in BAB compared to BAN with and without DHT stimulation. 
Figure S7: Overlap of down-regulated vasculature-related genes in BAB as compared to BAN with and 
without DHT treatment. 
Figure S8: Trend analysis of significantly expressed genes in non-balding (BAN) and balding DPC 
(BAB) under DHT treatment. 
Table S1: (a) Expression level of DP signature genes in non-balding (BAN) and balding (BAB) DPC. (b) 
Expression level of DP signature genes in primary balding DPC and primary non-balding DPC. (c) 
Expression level of DP signature genes in primary DPC (HFDPC) and primary fibroblast (NHDF and L5-
F). 
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Table S2: (a) Commonly up-regulated genes in BAB compared to BAN under 1 nM and 10 nM DHT 
stimulation. (b) Commonly down-regulated genes in BAB compared to BAN under 1 nM and 10 nM 
DHT stimulation  
Table S3: (a) Detailed list of vasculature-related genes that are down-regulated in balding DPC (BAB) 
compared to non-balding DPC (BAN) with DHT treatment. (b) List of vasculature-related genes that are 
down-regulated in balding DPC (BAB) compared to non-balding DPC (BAN) without DHT treatment. (c) 
List of vasculature-related genes that are down-regulated in primary balding DPC as compared to primary 
non-balding DPC. (d) Expression level of vasculature-related genes in primary fibroblast. 
Table S4: (a) Top functional enrichment clusters of down-regulated genes in BAB compared to BAN 
under 1 nM and 10 nM DHT stimulation. (b) Top functional enrichment clusters of up-regulated genes in 
BAB compared to BAN under 1 nM and 10 nM DHT stimulation. 
Table S5: qPCR validation primer sequences 
Table S6: (a) Up-regulated genes in BAB compared to BAN without DHT stimulation. (b) Down-
regulated genes in BAB compared to BAN without DHT stimulation. 
Table S7: (a) Top functional enrichment clusters of down-regulated genes in BAB compared to BAN 
without DHT stimulation. (b) Top functional enrichment clusters of up-regulated genes in BAB compared 
to BAN without DHT stimulation. 
Table S8: Overlap of expressed genes in BAB and BAN and differentially-expressed genes identified in 
BAB compared to BAN with AGA risk loci of genome-wide significance 
Table S9: (a) Motif analysis in promoter regions of down-regulated genes in BAB compared to BAN 
under DHT treatment (b) Motif analysis in promoter regions of up-regulated genes in BAB compared to 
BAN under DHT treatment. (c) Up-regulated genes in BAB compared to BAN with NFY and Sp1 
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binding motif in the promoter. (d) Up-regulated genes in BAB compared to BAN with E2F, NYF and 
CHR promoter motifs. 
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a b
c d
e
APOD
ARHGEF3
BMP4
DIO2
FOXO1
GAS7
GMFG
GUCY1A3
IFI27
LXN
LZTS1
NOG
PLCG2
RBP1
BMP2
CCND2
GPM6B
MEF2C
SOSTDC1
STON1
ACACB H3F3B PHF15 SPRY4
ALPL HBEGF PIK3R1 SVIL
BAMBI HEY1 PLA2G4A SYNM
BCL2 INHBB PTGS2 TFAP2A
CASP1 JARID2 PTPRE TFAP2C
CLCA2 LEF1 RABGAP1L THBD
CPE LRP4 RGS2 TMEM100
CREM LYN RNF144A TNFAIP3
CSGALNACT1 METTL7A RORA TRIM2
CSTA MIPEP SAT1 TRPS1
CTSH MITF SDC1 TWIST1
CYP26B1 MLLT11 SEMA4C VAV3
DYNC1I1 MMD SERPINI1 VCAN
EDNRA MTSS1 SETBP1 WNT5A
FABP5 MYLIP SLC7A8 ZMYND8
FGF7 NDP SLCO3A1
FRZB NET1 SNCAIP
GPR125 NLRP1 SPRY1
LPL
MAF
MGP
MREG
MTUS1
NTRK2
PEG3
PIK3R3
RASL11B
SFN
SNAI1
SPARCL1
SPON1
WIF1
A2M
ALX4
APOE
AQP1
CRIP2
EDN3
EGR3
ETV1
GPRC5B
HEY2
HLA-DPB1
IGF1
LAMC3
LHCGR
Expressed in BAN 
only
Expressed 
in BAB 
only
Expressed in both BAB and BAN
Not expressed in 
both BAB and BAN
Total: 14 
Total: 69 
Total: 6 
Total: 28 
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